Tag Archives: Pancreatic

Byetta Lawsuit Website Launched by Bernstein Liebhard LLP Gives Updated Byetta Pancreatic Cancer Details, Developing Investigation and Litigation

Posted on by


New York, NY (PRWEB) June 28, 2013

Bernstein Liebhard LLP has launched a new Byetta lawsuit website devoted to supplying data to patients who could have created pancreatitis, pancreatic cancer or thyroid cancer as a result of the diabetes drug.

&#13

The Firm is actively investigating the hazardous pancreatic dangers related with Byetta, a sort II diabetes drug involved in a class of drugs known as incretin mimetics. In addition to its new internet site, which contains information associated to side effects, as effectively as updates on the increasing nationwide litigation involving Byetta and other incretin mimetics which includes Januvia, Bernstein Liebhard LLP is providing totally free and confidential case evaluations to any person who may possibly have been diagnosed with any of the following diseases soon after taking the diabetes medication:&#13

&#13

Januvia Lawsuit Web site Launched by Bernstein Liebhard LLP to Give Information About Possible Januvia Side Effects, Such as Januvia Pancreatic Cancer

Posted on by


New York, New York (PRWEB) July 03, 2013

A new Januvia lawsuit internet site has been launched by Bernstein Liebhard LLP to supply details to men and women who might be concerned about potential Januvia side effects, such as Januvia pancreatic cancer, Januvia pancreatitis and Januvia thyroid cancer. The internet site will also be updated regularly with the most existing data concerning the increasing litigation surrounding the type 2 diabetes drug and its alleged association with pancreatic cancer, pancreatitis, and thyroid cancer.

&#13

Januvia and comparable variety 2 diabetes drugs are coming beneath elevated scrutiny amid concerns that they may possibly boost the danger that a patient will develop pancreatic cancer, pancreatitis or thyroid cancer. This site will offer valuable info to worried sufferers and their households concerning the prospective risks connected with Januvia, as effectively as their choices for legal recourse, says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and healthcare devices. The Firm is currently offering free of charge Januvia lawsuit consultations to any person who might have been harmed right after taking Januvia or a similar drug.

&#13

Januvia Lawsuits

&#13

Januvia belongs to a class of type2 diabetes drugs identified as incretin mimetics, which support regulate blood sugar by stimulating insulin production by the pancreas. The U.S. Food &amp Drug Administration (FDA) announced in March that it was investigating incretin mimetics following benefits from an unpublished study indicated these drugs may possibly cause pre-cancerous adjustments in the pancreas.* Most recently, a report published June 10th in the British Health-related Journal revealed previously unpublished information that indicated the producers of incretin mimetics could have downplayed the drugs possible to harm the pancreas.**

&#13

In 2009, a caution relating to a possible Januvia pancreatitis threat was added to the drugs label right after the FDA became conscious of 88 post-advertising cases of acute pancreatitis in individuals taking Januvia.*** In 2011, a study published in Gastroenterology discovered that use of Januvia appeared to increase the danger of pancreatitis and pancreatic cancer, while two circumstances of thyroid cancer have been also reported in the individuals who took Januvia.****

&#13

Court documents indicate that Merck &amp Co. has been named in a quantity of lawsuits filed on behalf of individuals who allegedly developed Januvia pancreatic cancer, Januvia pancreatitis, or Januvia thyroid cancer. The U.S. Judicial Panel on Multidistrict Litigation (JPML) is scheduled to hear Oral Arguments on July 25, 2013, relating to the proposed establishment of a multidistrict litigation for all federally-filed claims involving incretin mimetics, Which includes Januvia lawsuits. (In Re: Incretins Items Liability, Sales and Advertising and marketing Litigation, MDL 2452, JPML)

&#13

Individuals who have allegedly developed Januvia pancreatic cancer, thyroid cancer or pancreatitis could be entitled to compensation for medical bills, lost wages, pain and suffering and far more. To learn more about filing a Januvia lawsuit, please check out Bernstein Liebhard LLPs internet site. For a lot more info, please call 800-511-5092.

&#13

*fda.gov/Drugs/DrugSafety/ucm343187.htm&#13

**bmj.com/open-data/incretin#alternate BMJ, June 10, 2013&#13

**fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm September 25, 2009 &#13

***gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011

&#13

About Bernstein Liebhard LLP &#13

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex person and class action lawsuits nationwide considering that 1993, including these who have been harmed by hazardous drugs, defective health-related devices and consumer items. The firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the leading plaintiffs firms in the country, for the previous ten consecutive years.

&#13

Bernstein Liebhard LLP &#13

10 East 40th Street &#13

New York, New York 10016 &#13

800-511-5092

&#13

Lawyer Marketing.

New Time Eligibility Announced for Byetta Pancreatic Cancer Allegation Circumstances Getting Reviewed by Resource4thePeople Attorneys

Posted on by

San Diego, CA (PRWEB) June 28, 2013

http://www.resource4thepeople.com/defectivedrugs/byetta.html

&#13

Resource4thePeople announced right now extended time eligibilities for customers who are in search of legal consultations more than allegations that their use of a class of diabetes drug including Byetta might have triggered them to suffer severe side effects of the pancreas.

&#13

“This announcement is being created in order to clarify the status of buyers who have been inquiring about their legal rights because the Meals and Drug Administration’s March 14, 2013 announcement* about its investigation into feasible hyperlinks among these medicines and pancreatitis and cancer,” stated Resource4thePeople.&#13

“Therefore, we are announcing that shoppers who may possibly have been using the drugs just before and soon after the announcement are each eligible to seek consultations with our national legal network.”

&#13

Resource4thePeople is informing customers that if they have any confusion about their status in possibly looking for compensation for alleged side effects they should take actions now to preserve their legal rights.

&#13

The complimentary consultations have been offered in response to a large volume of inquiries from shoppers triggered by the FDA’s announcement that it is investigating reports of feasible enhanced risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs such as Byetta for type 2 diabetes.

&#13

The FDA identified these drugs as exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto).

&#13

There are a substantial quantity of Americans who treat their diabetes with these drugs and the FDA announcement has had widespread ramifications in terms of individuals seeking info about their legal possibilities, stated Resource4thePeople.

&#13

As a outcome, our national legal network will continue to provide cost-free legal consultations in which customers might decide their eligibility to file a claim or lawsuit and seek compensation for the healthcare expenses, discomfort and suffering and other charges that might have been incurred.

&#13

In its announcement, an FDA spokesman said that the findings were based on examination of a modest number of pancreatic tissue specimens taken from patients following they died from unspecified causes.

&#13

The FDA has asked researchers to provide the methodology utilised to gather and study these specimens and to give the tissue samples so the agency can additional investigate possible pancreatic toxicity linked with the incretin mimetics.

&#13

Resource4thePeople notes that there may possibly be legal time limits involved in such actions and is requesting buyers to make make contact with as soon as achievable in order to preserve all legal options obtainable.

&#13

Byetta was initially authorized by the FDA and released onto the marketplace in 2005, with its primary function being to help individuals with diabetes manage their situation.

&#13

It is applied by injection and it and the other incretin mimetics, according to the FDA, mimic the incretin hormones that the body typically produces naturally to stimulate the release of insulin in response to a meal.

&#13

The agency stated the medications are used along with diet and workout to reduced blood sugar in adults with sort two diabetes.

&#13

In its announcement, the FDA reiterated a preceding public warning about postmarketing reports of acute pancreatitis, such as fatal and serious nonfatal situations, associated with the use of incretin mimetic drugs exenatide and sitagliptin.

&#13

An agency official also mentioned that a not too long ago published study that examined insurance coverage records also found the use of exenatide or sitagliptin could double the risk of building acute pancreatitis.

&#13

The official mentioned that the Warnings and Precautions section of the drug labels and the patient Medication Guides for incretin mimetics contain warnings about the threat of acute pancreatitis.

&#13

Resource4thePeople also is delivering consumers some of the cautionary analysis about Byetta and its sister drugs. Right here are some of the warnings and precautions taken from the agencys internet internet site:**

&#13

What is the most essential info I should know about BYETTA?&#13